Skip to main content
PepStack

Sermorelin

GH Secretagogue
GHRH(1-29)GRF 1-29

Overview

Sermorelin, also known as GHRH(1-29) or GRF 1-29, is a synthetic peptide analog of the naturally occurring growth hormone-releasing hormone (GHRH). It consists of the first 29 amino acids of the full 44-amino acid sequence of GHRH, which is sufficient to retain full biological activity. Sermorelin is synthesized using solid-phase peptide synthesis techniques, which allow for precise control over the sequence and purity of the peptide. It is primarily used in research settings to study growth hormone dynamics and related physiological processes. Researchers have investigated Sermorelin primarily in the context of growth hormone deficiency and its potential to stimulate endogenous growth hormone secretion. Studies have shown that Sermorelin can effectively increase growth hormone levels in both children and adults with growth hormone deficiencies. Additionally, it has been explored for its potential benefits in age-related conditions, given its ability to enhance growth hormone levels. The mechanism of action of Sermorelin involves binding to the growth hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs, stimulating the synthesis and release of growth hormone. This interaction mimics the natural physiological process of growth hormone regulation, making it a valuable tool for studying endocrine function. Pharmacokinetically, Sermorelin has a relatively short half-life, with researchers reporting a range of approximately 10 to 20 minutes following intravenous administration. Its bioavailability is limited when administered orally, necessitating parenteral routes for effective delivery. Current research on Sermorelin is focused on its therapeutic potential and safety profile. It is not approved as a medicinal product in many regions, and its use is primarily restricted to research settings. Regulatory agencies have not classified it as a controlled substance, but its legal status can vary by country and region.

Mechanism of Action

Sermorelin acts by binding to the growth hormone-releasing hormone receptor (GHRHR) on the pituitary gland, stimulating the release of growth hormone. This interaction activates the cAMP signaling pathway, leading to increased synthesis and secretion of growth hormone.

Molecular Data

FormulaC149H246N44O42S
Molecular Weight3357.9 g/mol
CAS Number86168-78-7
PubChem CID16132413

Half-Life

SubcutaneousData limited
IntramuscularData limited
Intravenous~10 to 20 minutes
IntranasalNot applicable
OralPoor bioavailability

Due to its peptide nature, Sermorelin is rapidly degraded in the gastrointestinal tract, limiting its oral bioavailability.

Storage

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Solubility

Sermorelin is soluble in water and aqueous buffers.

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Not approved by the FDA as a medicinal product. Not a controlled substance.

🇦🇺AU

Not approved by the TGA as a medicinal product.

🇬🇧UK

Not approved by the MHRA as a medicinal product.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

6 Research Publications

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Unknown

Analytical biochemistry · 2023

Researchers developed a new method to detect growth hormone-releasing hormones (GHRHs) in urine, which are banned in sports. This method improves the analysis of these substances, making it easier to identify them at low concentrations in complex urine samples.

  • Researchers observed that the new method effectively detects GHRHs like tesamorelin and CJC-1295 in urine samples.
  • The study highlights the challenges of analyzing GHRHs due to their low concentrations.
  • This method offers a more efficient alternative to existing techniques for monitoring banned substances in sports.
PubMed

In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides.

Unknown

Biomedical chromatography : BMC · 2023

Researchers studied the stability of certain peptides related to growth hormone and their potential use as internal standards for measuring peptide levels in biological samples. They found that specific peptides, GHRP-4, GHRP-6, and Sermorelin (22-29), remained stable when exposed to human blood and enzymes, making them suitable for accurate analysis.

  • Researchers observed that the matrix effect and sample pretreatment significantly influence peptide recovery in biological samples.
  • GHRP-4, GHRP-6, and Sermorelin (22-29) were identified as stable internal standards for quantifying peptides.
  • The study established a unique profile for each peptide regarding its stability and protein binding.
PubMed

Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis.

Unknown

Electrophoresis · 2023

Researchers developed a new method to analyze specific growth hormone-releasing hormone (GHRH) analogs that athletes may misuse. They successfully separated these compounds using advanced techniques, achieving high sensitivity in detecting them in urine samples.

  • The method allowed for the first-time separation of enantiomeric GHRH analogs, which differ by the chirality of one amino acid.
  • A significant increase in detection sensitivity was achieved using a large volume sample stacking technique.
  • The optimized method successfully detected GHRH analogs in urine with a signal enhancement factor of 640.
PubMed

An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.

Unknown

Journal of pharmaceutical and biomedical analysis · 2022

Researchers developed a new method to detect specific growth hormone-releasing hormones in urine without using antibodies. They found that this technique is highly sensitive and cost-effective, allowing for the identification of these hormones at very low concentrations. Additionally, proper handling of urine samples is crucial to prevent hormone degradation.

  • The new ultrafiltration-based method can detect hormone levels as low as 5 pg/mL.
  • This approach achieved higher recovery rates and similar sensitivity compared to traditional antibody-based methods, but at lower costs.
  • Researchers highlighted the importance of sample handling, as certain hormones degrade quickly under improper conditions.
PubMed

PEGylation of growth hormone-releasing hormone (GRF) analogues.

Review

Advanced drug delivery reviews · 2003

Researchers studied a modified version of a growth hormone-releasing hormone (GRF) to improve its stability in the body. They found that attaching polyethylene glycol (PEG) to the GRF significantly increased its effectiveness and duration of action, which could enhance growth hormone levels in the body.

  • Researchers observed that PEGylation improved the stability and half-life of GRF in the body.
  • The study found that different PEGylated GRF variants showed varying levels of biological activity.
  • Mono-PEGylated versions of GRF demonstrated similar or greater effectiveness in stimulating growth hormone release compared to the unmodified version.
PubMed

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

Review

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999

Researchers reviewed the use of sermorelin, a synthetic hormone, in diagnosing and treating children with growth hormone deficiency. They found that sermorelin effectively stimulates growth hormone release and can promote growth in some prepubertal children with this condition.

  • Sermorelin is a useful tool for diagnosing growth hormone deficiency, with fewer false positives compared to other tests.
  • Daily use of sermorelin showed significant increases in height velocity in many children over a 12-month period.
  • The long-term effects of sermorelin on final adult height are still being studied.
PubMed

Track Sermorelin in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp StoreGet it onGoogle Play

This page is for informational and research purposes only. All information is based on published scientific literature. Nothing on this page constitutes medical advice or replaces consultation with a qualified healthcare professional.